课题基金 / 基金详情

Cost-effectiveness of Pharmacogenomic-guided (PGX) Approach to Warfarin Therapy among Patients diagnosed with Atrial Fibrillation: Experimental Evidence from Ontario

Cost-effectiveness of Pharmacogenomic-guided (PGX) Approach to Warfarin Therapy among Patients diagnosed with Atrial Fibrillation: Experimental Evidence from Ontario
药物基因组学指导 (PGX) 方法对诊断为心房颤动的患者进行华法林治疗的成本效益：来自安大略省的实验证据
批准号：
386422
负责人：
Hafeez Aneeka
金额：
$1.27万
依托单位：
University of Western Ontario
依托单位国家：
加拿大
项目类别：
Studentship Programs
财政年份：
2017
资助国家：
加拿大
项目状态：
已结题
起止时间：
2017-12-01 至 2018-12-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=386422&lang=en
关键词：
Atrial Fibrillation Cost-Effectiveness Personalized Medicine Pharmacogenomic-Guided (Pgx) Care Model Warfarin

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
房颤（AF）是一种由不规则快速心跳定义的疾病，通常通过称为华法林的抗凝剂治疗，以降低中风和栓塞的风险。然而，华法林具有狭窄的治疗窗口和严格的
英文摘要
Atrial fibrillation (AF) is a condition defined by the presence of irregular rapid heartbeats and commonly treated by an anticoagulant called warfarin to reduce the risk of stroke and embolism. However, warfarin has a narrow therapeutic window and rigorou
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金